[go: up one dir, main page]

WO2001077341A3 - Mammalian heparanase - Google Patents

Mammalian heparanase Download PDF

Info

Publication number
WO2001077341A3
WO2001077341A3 PCT/EP2001/003878 EP0103878W WO0177341A3 WO 2001077341 A3 WO2001077341 A3 WO 2001077341A3 EP 0103878 W EP0103878 W EP 0103878W WO 0177341 A3 WO0177341 A3 WO 0177341A3
Authority
WO
WIPO (PCT)
Prior art keywords
mammalian heparanase
heparanase
polynucleotide molecules
provides
mammalian
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2001/003878
Other languages
French (fr)
Other versions
WO2001077341A2 (en
Inventor
Gerda Martha Cornelia Smets
Joerg Juergen Sprengel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Priority to AU2001254780A priority Critical patent/AU2001254780A1/en
Publication of WO2001077341A2 publication Critical patent/WO2001077341A2/en
Publication of WO2001077341A3 publication Critical patent/WO2001077341A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01166—Heparanase (3.2.1.166)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention provides isolated mammalian heparanase polypeptides, and the isolated polynucleotide molecules that encode them, as well as vectors and host cells comprising such polynucleotide molecules. The invention also provides a method for identification of an agent that alters heparanase activity.
PCT/EP2001/003878 2000-04-11 2001-04-05 Mammalian heparanase Ceased WO2001077341A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001254780A AU2001254780A1 (en) 2000-04-11 2001-04-05 Mammalian heparanase

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0008912.8 2000-04-11
GBGB0008912.8A GB0008912D0 (en) 2000-04-11 2000-04-11 Mammalian heparanase

Publications (2)

Publication Number Publication Date
WO2001077341A2 WO2001077341A2 (en) 2001-10-18
WO2001077341A3 true WO2001077341A3 (en) 2002-03-21

Family

ID=9889694

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/003878 Ceased WO2001077341A2 (en) 2000-04-11 2001-04-05 Mammalian heparanase

Country Status (3)

Country Link
AU (1) AU2001254780A1 (en)
GB (1) GB0008912D0 (en)
WO (1) WO2001077341A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001287610A1 (en) * 2000-07-12 2002-01-21 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw A second human heparanase, and splice variants thereof, with a predominant expression in skeletal muscle, heart and pancreas
CN100462432C (en) * 2006-03-15 2009-02-18 中国人民解放军军事医学科学院野战输血研究所 Hybridoma cell strain, and anti-human heparin enzyme monoclonal anti-body produced by it

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206223A (en) * 1986-06-26 1993-04-27 Yeda Research And Development Co. Ltd. Method for inhibiting heparanase activity
WO1999021975A1 (en) * 1997-10-28 1999-05-06 The Australian National University Isolated nucleic acid molecule encoding mammalian endoglucuronidase and uses therefor
WO1999043830A2 (en) * 1998-02-24 1999-09-02 Pharmacia & Upjohn Company Human platelet heparanase polypeptides, polynucleotide molecules that encode them, and methods for the identification of compounds that alter heparanase activity
WO2001021814A1 (en) * 1999-09-23 2001-03-29 Merck Patent Gmbh Heparanase-2, a member of the heparanase protein family
WO2001046392A2 (en) * 1999-12-22 2001-06-28 Oxford Glycosciences (Uk) Ltd. Homologues of human heparanase and splice variants thereof
WO2001048161A2 (en) * 1999-12-23 2001-07-05 Schering Aktiengesellschaft Human heparanase-related polypeptide and nucleic acid

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206223A (en) * 1986-06-26 1993-04-27 Yeda Research And Development Co. Ltd. Method for inhibiting heparanase activity
WO1999021975A1 (en) * 1997-10-28 1999-05-06 The Australian National University Isolated nucleic acid molecule encoding mammalian endoglucuronidase and uses therefor
WO1999043830A2 (en) * 1998-02-24 1999-09-02 Pharmacia & Upjohn Company Human platelet heparanase polypeptides, polynucleotide molecules that encode them, and methods for the identification of compounds that alter heparanase activity
WO2001021814A1 (en) * 1999-09-23 2001-03-29 Merck Patent Gmbh Heparanase-2, a member of the heparanase protein family
WO2001046392A2 (en) * 1999-12-22 2001-06-28 Oxford Glycosciences (Uk) Ltd. Homologues of human heparanase and splice variants thereof
WO2001048161A2 (en) * 1999-12-23 2001-07-05 Schering Aktiengesellschaft Human heparanase-related polypeptide and nucleic acid

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DATABASE EM_EST EMBL; 6 January 2000 (2000-01-06), NCI-CGAP, XP002181947 *
DATABASE EM_RO EMBL; 2 November 1999 (1999-11-02), PODYMA K A ET AL: "Heparanase from parathyroid cell line", XP002181948 *
KISILEVSKY R ET AL: "ARRESTING AMYLOIDOSIS IN VIVO USING SMALL-MOLECULE ANIONIC SULPHONATES OR SULPHATES: IMPLICATIONS FOR ALZHEIMER'S DISEASE", NATURE MEDICINE, NATURE PUBLISHING, CO, US, vol. 1, no. 2, 1 February 1995 (1995-02-01), pages 143 - 148, XP000611547, ISSN: 1078-8956 *
KOSIR M A ET AL: "Degradation of basement membrane by prostate tumor heparanase", JOURNAL OF SURGICAL RESEARCH, ACADEMIC PRESS INC., SAN DIEGO, CA, US, vol. 81, no. 1, January 1999 (1999-01-01), pages 42 - 47, XP002155606, ISSN: 0022-4804 *
MCKENZIE E ET AL: "Cloning and expression profiling of hpa2, a novel mammalian heparanase family member", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 276, no. 3, 5 October 2000 (2000-10-05), pages 1170 - 1177, XP002155087, ISSN: 0006-291X *
NAKAJIMA M ET AL: "HEPARANASES AND TUMOR METASTASIS", JOURNAL OF CELLULAR BIOCHEMISTRY, vol. 36, no. 2, 1988, pages 157 - 168, XP001030761, ISSN: 0730-2312 *

Also Published As

Publication number Publication date
WO2001077341A2 (en) 2001-10-18
GB0008912D0 (en) 2000-05-31
AU2001254780A1 (en) 2001-10-23

Similar Documents

Publication Publication Date Title
WO1999036550A3 (en) Human protease molecules
WO1999043830A3 (en) Human platelet heparanase polypeptides, polynucleotide molecules that encode them, and methods for the identification of compounds that alter heparanase activity
WO2001012662A3 (en) Membrane associated proteins
WO2001098468A3 (en) Proteases
WO2000061622A3 (en) Genes associated with diseases of the kidney
WO2000009709A3 (en) Proteases and associated proteins
WO2002008396A3 (en) Human proteases
WO2001010903A3 (en) Proteases and protease inhibitors
WO2000026245A3 (en) Human membrane transport proteins
WO2000017355A3 (en) Human cytoskeleton associated proteins
WO2001016334A3 (en) Human hydrolytic enzymes
WO2000052151A3 (en) Human secretory proteins
WO2000044900A3 (en) Nucleic-acid binding proteins
WO2001007471A3 (en) Cell cycle and proliferation proteins
WO1999058558A3 (en) Cell signaling proteins
WO2001044448A3 (en) Human oxidoreductase proteins
WO2002038744A3 (en) Proteases
WO2001071004A3 (en) Proteases
WO2001032888A3 (en) Human transferase molecules
WO2000020604A3 (en) Oxidoreductase molecules
WO1999041387A3 (en) Prostate-associated serine protease
WO2000028045A3 (en) Human hydrolase proteins
WO1999041373A3 (en) Human transport-associated molecules
WO2001077341A3 (en) Mammalian heparanase
WO1999015659A3 (en) Human ubiquitin-conjugating enzymes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP